XNAS · Healthcare · Biotechnology
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Massive revenue collapse (-1614% YoY) to just $1M despite $0.43 EPS beat signals severe operational distress. Biotech struggling with product commercialization amid deteriorating fundamentals.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | Q1 2026 | -0.66 | -0.23 | +65.15% | $1.5M | ✅ Beat | -1.08% | -4.19% | — |
| 2026-03-05 | Q4 2025 | -0.63 | -0.56 | +11.11% | $1.9M | ✅ Beat | -0.57% | -4.99% | -3.67% |
| 2025-11-20 |
| Q3 2025 |
| -0.82 |
| -0.24 |
| +70.73% |
| $5.4M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-14 | Q2 2025 | -0.56 | -1.23 | -119.64% | $5.7M | mixed | +5.07% | -6.35% | -3.93% |
| 2025-03-19 | Q4 2024 | -0.61 | -0.36 | +40.98% | $5.8M | ✅ Beat | -6.73% | -9.57% | -3.45% |
| 2024-11-26 | Q3 2024 | -0.44 | -0.98 | -122.73% | $4.4M | ❌ Miss | +3.25% | +8.99% | +5.50% |
| 2024-08-14 | Q2 2024 | -0.44 | -0.68 | -54.55% | $5.1M | ❌ Miss | +4.01% | +7.27% | +1.26% |
| 2024-05-29 | Q1 2024 | -0.41 | -0.39 | +4.88% | $5.0M | ✅ Beat | +0.19% | +6.18% | -3.06% |
Showing last 8 quarters.